Dozens Of Generic Makers And Pharmacies Won’t Face Lawsuits Over Zantac And Cancer Risks
Dec 19, 2023
A federal court judge dismissed all claims against dozens of generic manufacturers and retailers in sprawling litigation over allegations that the Zantac heartburn pill may contain a carcinogen, although brand-name drug makers will continue to face more than 1,400 lawsuits over the issue. The ruling is the latest chapter in an ongoing saga of the widely used heartburn medicine, which is also known as ranitidine.
Radiation Oncologists Met With Congressional Leaders to Reverse CMS Cuts and Provide Equal Access to Care
Radiation oncologists met with Congress to urge leaders to consider how the Medicare and Medicaid Services (CMS) proposal to make significant cuts to radiation oncology facilities could be detrimental to the survival of patients with Read more…
FDA Approves Neoadjuvant Pembrolizumab Combination for Early TNBC Indication
The FDA granted approval to the supplemental biologics license application (sBLA) for pembrolizumab (Keytruda) as neoadjuvant therapy for patients with high-risk early-stage triple-negative breast cancer (TNBC) when given in combination with chemotherapy followed by single-agent Read more…
Recommended TVUS Screening Thresholds May Miss Endometrial Cancer in Black Women
Adherence to current clinical guidelines for the evaluation of postmenopausal bleeding may result in systematic underdiagnosis of endometrial cancer (EC) in Black women, according to a study published online July 15 in JAMA Oncology. Kemi M. Read more…